Diabetic retinopathy

Last updated

Diabetic retinopathy
Other namesDiabetic eye disease
Fundus - diabetic retinopathy.png
Fundus image, showing several common signs of diabetic retinopathy
Pronunciation
  • ˌrɛtɪnˈɑpəθi [1]
Specialty Ophthalmology, optometry
Symptoms Often asymptomatic, but can cause spots in the eye and vision loss.
Complications Vitreous hemorrhage, Retinal detachment, Glaucoma, Blindness
DurationLifelong
CausesLong-term poor control of diabetes mellitus
Risk factors Diabetes, poor control of blood sugar, smoking, inflammation
Diagnostic method Eye examination [2]
Treatment Laser coagulation, Vitrectomy [2]
Medication Anti-VEGF Injection [2]
FrequencyNearly all patients with type 1 diabetes and >60% of patients with type 2 diabetes [3]

Diabetic retinopathy (also known as diabetic eye disease), is a medical condition in which damage occurs to the retina due to diabetes. It is a leading cause of blindness in developed countries and one of the lead causes of sight loss in the world, even though there are many new therapies and improved treatments for helping people live with diabetes. [4]

Contents

Diabetic retinopathy affects up to 80 percent of those who have had both type 1 and type 2 diabetes for 20 years or more. In at least 90% of new cases, progression to more aggressive forms of sight threatening retinopathy and maculopathy could be reduced with proper treatment and monitoring of the eyes. The longer a person has diabetes, the higher his or her chances of developing diabetic retinopathy. Each year in the United States, diabetic retinopathy accounts for 12% of all new cases of blindness. It is also the leading cause of blindness in people aged 20 to 64.

Signs and symptoms

Proliferative diabetic retinopathy Fundus Proliferative retinopathy EDA01.JPG
Proliferative diabetic retinopathy
Emptied retinal venules due to arterial branch occlusion in diabetic retinopathy (fluorescein angiography) Retinal branch occlusion ratkaj.jpg
Emptied retinal venules due to arterial branch occlusion in diabetic retinopathy (fluorescein angiography)

Nearly all people with diabetes develop some degree of retina damage ("retinopathy") over several decades with the disease. For many, that damage can only be detected by a retinal exam, and has no noticeable effect on vision. [5] Over time, progressive retinal damage may appear on a retinal exam, first with small bulges in retinal blood vessels called microaneurysms. Then larger abnormalities in retinal vessels: cotton wool spots, hemorrhages, lipid deposits called "hard exudates", intraretinal microvascular abnormalities, and abnormal-looking retinal veins. [5] Eventually, many progress to a stage where new blood vessels grow throughout the retina. These new blood vessels often break and bleed. Minor bleeding can cause dark floating spots obstructing vision; major bleeding can completely block vision. [6]

Around half of people with diabetic retinopathy develop swelling of the macula, called macular edema, which can begin at any time. [6] If the swelling occurs near the center of the macula, it can cause vision disruptions ranging from mildly blurred vision to severe loss of the center of an affected person's visual field. [7] Left untreated, around 30% of those with such swelling experience vision disruption over the next 3–5 years. [8] Macular edema is the most common cause of vision loss in people with diabetic retinopathy. [5]

The repeated processes of blood vessel growth, swelling, and scarring can eventually cause retinal detachment, which manifests as the sudden appearance of dark floating spots, flashes of light, or blurred vision. [9] [10]

Diagnosis and classification

Diabetic retinopathy is typically diagnosed by retinal exam observations using ophthalmoscopy. [11] The American Academy of Ophthalmology divides diabetic retinopathy into five categories of progressive severity. The first category, "no apparent retinopathy", describes those with a healthy retinal exam. [5] The next three categories: mild, moderate, and severe nonproliferative diabetic retinopathy (NPDR) describe increasing levels of damage to the retina. People with mild NPDR have microaneurysms in the retina, but no other damage. Those with severe NPDR have 20+ retinal hemorrhages in each quadrant of the retina, a distinctive pattern of damage on the veins of the retina called "venous beading" in at least two retinal quadrants, and obvious intraretinal microvascular abnormalities anywhere on the retina. Moderate NPDR is defined as more severe than mild NPDR, but not yet meeting the criteria for severe NPDR. [5] The fifth stage, proliferative diabetic retinopathy, is for those with new blood vessels forming throughout the retina ("retinal neovascularization"), or blood leaking into the vitreous humor ("vitreous hemorrhage") or between the vitreous membrane and retina ("preretinal hemorrhage"). [5]

The same guidelines separately divide macular edema into two categories: "macular edema apparently absent" and "macular edema apparently present". The latter is further subdivided into "mild"—retinal thickening or lipid deposits far from the macula's center; "moderate"— thickening or deposits near the center; and "severe"—thickening or deposits on the macula center. [5] Optical coherence tomography is frequently used to assess macular edema. [11]

Fluorescein angiography is used by retina specialists to further assess diabetic retinopathy severity and to determine sites of macular damage. [11] [12]

Screening

Due to the lack of symptoms, most people with diabetic retinopathy are unaware that they have the condition until they visit an eye doctor. [13] Both the American Diabetes Association (ADA) and the International Council of Ophthalmology (ICO) recommend regular eye exams for those with diabetes to screen for diabetic retinopathy (except those with gestational diabetes). [14] The ADA recommends a comprehensive eye examination at the time of type 2 diabetes diagnosis, and within five years of the onset of type 1 diabetes. For women with diabetes who become pregnant, the ADA recommends an eye examination before pregnancy, in each trimester, and for a year post partum. [14] The ICO recommends eye examinations for those with diabetes include a visual acuity examination and a retinal examination via ophthalmoscopy or retinal photography. [14]

Iceland, Ireland, and the United Kingdom are the only countries with full national diabetic retinopathy screening programs, while substantial regional screening programs have been implemented in parts of mainland Europe, parts of Asia, and Botswana. [15] In the UK, screening for diabetic retinopathy is part of the standard of care for people with diabetes. [16] After one normal screening in people with diabetes, further screening is recommended every year. [17] Teleophthalmology has been employed in these programs. [18]

Causes

Diabetic retinopathy is caused by prolonged high blood glucose damaging the small blood vessels of the retina, [19] though the mechanism by which this occurs is unknown. [20] Progression of diabetic retinopathy is accompanied by loss of capillary cells, increased blood vessel permeability in the retina, and altered retinal blood flow, all of which can reduce the amount of blood oxygen that gets delivered to the retina. [21] Poor oxygenation of tissues drives the formation of new blood vessels throughout the retina, resulting in the proliferative stage of disease. [21] These new blood vessels tend to rupture easily, causing bleeding within the eye, scarring, and damage to the retina or macula. [21] Recent evidences have found a strong association between diabetic retinopathy and inflammation. [7]

Risk factors

The major risk factors for developing diabetic retinopathy are duration of diabetes, poor blood sugar control, and to a lesser extent high blood pressure. [22] Five years after diabetes diagnosis, around 25% of those with type 1 diabetes have some degree of diabetic retinopathy, while 2% have proliferative diabetic retinopathy. By 15 years after diagnosis, that increases to 80% with some retinopathy, and 25% with proliferative disease. [23] Children are an exception—regardless of duration of diabetes, children rarely experience sight-threatening retinopathy; however, puberty can accelerate retinopathy progression. [23] Pregnancy can also accelerate the progression of diabetic retinopathy (although women with gestational diabetes are not at risk). [23]

Both chronically high blood sugar (measured by a high HbA1c) and highly variable blood sugar are associated with developing diabetic retinopathy. [24] Several more minor risk factors also exacerbate diabetic retinopathy, namely kidney disease, abnormal blood lipids, high body mass index, and smoking. [24]

Genetic predisposition to diabetic retinopathy in type 2 diabetes consists of many genetic variants across the genome that are collectively associated with diabetic retinopathy (polygenic risk) and overlaps with genetic risk for glucose, low-density lipoprotein cholesterol, and systolic blood pressure. [25] Several variations in the VEGFC gene have also been associated with an increased risk of developing macular edema. [26]

People with Down syndrome, who have extra chromosome 21 material, almost never acquire diabetic retinopathy. This protection appears to be due to the elevated levels of endostatin, [27] an anti-angiogenic protein, derived from collagen XVIII. The collagen XVIII gene is located on chromosome 21.

Incidence of Retinitis Pigmentosa is observed to result in fewer and less severe microvascular lesions in both humans and mouse models. [28] Retinitis Pigmentosa results in loss of rod receptors in the mid peripheral field, reducing the oxygen consumption that is linked with release of VEGF and growth of unwanted blood vessels in the retina.

Obstructive sleep apnea (OSA) has been associated with a higher incidence of diabetic eye disease due to blood desaturation caused by intermittent upper airway obstructions. Treatment for OSA can help reduce the risk of diabetic complications. [29]

Pathogenesis

Illustration depicting diabetic retinopathy Blausen 0312 DiabeticRetinopathy.png
Illustration depicting diabetic retinopathy

Diabetic retinopathy is the result of damage to the small blood vessels and neurons of the retina. The earliest changes leading to diabetic retinopathy include narrowing of the retinal arteries associated with reduced retinal blood flow; dysfunction of the neurons of the inner retina, followed in later stages by changes in the function of the outer retina, associated with subtle changes in visual function; dysfunction of the blood-retinal barrier, which protects the retina from many substances in the blood (including toxins and immune cells), leading to the leaking of blood constituents into the retinal neuropile. [30] Later, the basement membrane of the retinal blood vessels thickens, capillaries degenerate and lose cells, particularly pericytes and vascular smooth muscle cells. This leads to loss of blood flow and progressive ischemia, and microscopic aneurysms which appear as balloon-like structures jutting out from the capillary walls, which recruit inflammatory cells; and advanced dysfunction and degeneration of the neurons and glial cells of the retina. [30] [31] The condition typically develops about 10–15 years after receiving the diagnosis of diabetes mellitus.

An experimental study suggests that pericyte death is caused by blood glucose persistently activating protein kinase C and mitogen-activated protein kinase (MAPK), which, through a series of intermediates, inhibits signaling through platelet-derived growth factor receptors—signaling that supports cellular survival, proliferation, and growth. The resulting withdrawal of this signaling leads to the programmed cell death (apoptosis) of the cells in this experimental model. [32]

In addition, excessive sorbitol in diabetics is deposited on retina tissue and it is also proposed to play a role in diabetic retinopathy. [33]

Recent studies have found a strong correlation between retinal inflammation and diabetic retinopathy progression. [34] [35]

A genetic study showed that diabetic retinopathy shares a similar genetic predisposition with levels of glucose, low-density lipoprotein cholesterol, and systolic blood pressure, [25] indicating that glycemic control and cardiometabolic factors may be important in the development of diabetic retinopathy.

Lipid peroxidation plays a notable role in the progression of diabetic retinopathy. Free radicals such as hydroxyl and hydroperoxyl species with oxygen as functional group oxidize lipids and phospholipids, and at cellular level bring about membrane lipid peroxidation and in this way can trigger diabetic retinopathy. [36]

Management

There are four common treatments for diabetic retinopathy: anti-VEGF injections, steroid injections, panretinal laser photocoagulation, and vitrectomy. [37] Current treatment regimens can prevent 90% of severe vision loss. [38]

Although these treatments are very successful (in slowing or stopping further vision loss), they do not cure diabetic retinopathy. Caution should be exercised in treatment with laser surgery since it causes a loss of retinal tissue. It is often more prudent to inject triamcinolone or anti-VEGF drugs. In some patients it results in a marked increase of vision, especially if there is an edema of the macula. [39]

In addition, standard treatment for diabetic retinopathy includes improving control of blood sugar, blood pressure, and blood cholesterol, all of which can reduce diabetic retinopathy progression. [40]

Mild or moderate NPDR

For those with mild to moderate non-proliferative diabetic retinopathy, the American Academy of Ophthalmology recommends only more frequent retinal exams—every six to twelve months—as these people are at an increased risk of developing proliferative retinopathy or macular edema. [41] Injection of anti-VEGF drugs or steroids can reduce diabetic retinopathy progression in around half of eyes treated; however, whether this results in improved vision long term is not yet known. [42] The lipid-lowering drug fenofibrate also reduces progression of disease in people with mild to moderate disease. [43] [44]

Diabetic macular edema

Those at highest risk of vision loss – that is, with edema near the center of the macula – benefit most from eye injections of anti-VEGF therapies aflibercept, bevacizumab, or ranibizumab. [45] There is no widely accepted dosing schedule, though people typically receive more frequent injections during the first year of treatment, with less frequent injections in subsequent years sufficient to maintain remission. [40] Those whose eyes don't improve with anti-VEGF therapy may instead receive laser photocoagulation, typically in the form of short laser pulses. [46] Those with macular edema but no vision loss do not benefit from treatment; the American Academy of Ophthalmology recommends deferring treatment until visual acuity falls to at least 20/30. [47] The diabetic macular edema manifestation is difficult to predict. Autoantibodies against hexokinase 1 are commonly associated with diabetic macular edema manifestation. Nearly one-third of patients with diabetic macular edema were found to be positive for anti-hexokinase 1 autoantibodies. Importantly, these autoantibodies were rare in patients with diabetic retinopathy only or diabetes mellitus only. However, these autoantibodies fail to predict disease onset. They likely manifest secondary to the tissue-damaging stimulus at diabetic macular edema onset and cannot be used to predict diabetic macular edema before its onset. [48]

Laser photocoagulation

Image of fundus showing scatter laser surgery for diabetic retinopathy Fundus photo showing scatter laser surgery for diabetic retinopathy EDA09.JPG
Image of fundus showing scatter laser surgery for diabetic retinopathy

Laser photocoagulation can be used in two scenarios for the treatment of diabetic retinopathy. Firstly, to treat macular edema [49] and secondly, for treating whole retina (panretinal photocoagulation) for controlling neovascularization. It is widely used for early stages of proliferative retinopathy. There are different types of lasers and there is evidence available on their benefits to treat proliferative diabetic retinopathy. [50]

Panretinal laser photocoagulation

For those with proliferative or severe non-proliferative diabetic retinopathy, vision loss can be prevented by treatment with panretinal laser photocoagulation. [40]

The goal is to create 1,600–2,000 burns in the retina with the hope of reducing the retina's oxygen demand, and hence the possibility of ischemia. It is done in multiple sittings.

In treating advanced diabetic retinopathy, the burns are used to destroy the abnormal new blood vessels that form in the retina. This has been shown to reduce the risk of severe vision loss for eyes at risk by 50%. [51]

Before using the laser, the ophthalmologist dilates the pupil and applies anaesthetic drops to numb the eye. In some cases, the doctor also may numb the area behind the eye to reduce discomfort. The patient sits facing the laser machine while the doctor holds a special lens on the eye. The physician can use a single spot laser, a pattern scan laser for two dimensional patterns such as squares, rings and arcs, or a navigated laser which works by tracking retinal eye movements in real time. [52] [53] During the procedure, the patient will see flashes of light. These flashes often create an uncomfortable stinging sensation for the patient. After the laser treatment, patients should be advised not to drive for a few hours while the pupils are still dilated. Vision will most likely remain blurry for the rest of the day. Though there should not be much pain in the eye itself, an ice-cream headache like pain may last for hours afterwards.

Patients will lose some of their peripheral vision after this surgery although it may be barely noticeable by the patient. The procedure does however save the center of the patient's sight. Laser surgery may also slightly reduce colour and night vision.

A person with proliferative retinopathy will always be at risk for new bleeding, as well as glaucoma, a complication from the new blood vessels. This means that multiple treatments may be required to protect vision.

Medications

Intravitreal triamcinolone acetonide

Triamcinolone is a long acting steroid preparation. Treating people with DME with intravitreal injections of triamcinolone may lead to a some degree of improvement in visual acuity when compared to eyes treated with placebo injections. [54] When injected in the vitreous cavity, the steroid decreases the macular edema (thickening of the retina at the macula) caused due to diabetic maculopathy, and that may result in an increase in visual acuity. The effect of triamcinolone is not permanent and may last up to three months, which necessitates repeated injections for maintaining the beneficial effect. Best results of intravitreal Triamcinolone have been found in eyes that have already undergone cataract surgery. Complications of intravitreal injection of triamcinolone may include cataract, steroid-induced glaucoma, and endophthalmitis. [54]

Intravitreal anti-VEGF

Aflibercept may have advantages in improving visual outcomes over bevacizumab and ranibizumab, after one year, longer term advantages are unclear [55] In cases with vitreous hemorrhage, however, anti-VEGF injections proved to be less effective in restoring visual acuity than vitrectomy combined with panretinal laser-photocoagulation. [56]

Other

Fenofibrate, a drug that is also used to reduce cholesterol levels, has been studied for its role in helping to improve the negative effects caused by diabetes and reducing the occurrence of retinal inflammation. [4] There is some evidence that overall, in people with type II diabetes, fenofibrate may not make a clinically significant difference in progression of DME. [4] For people who have type II diabetes and have overt retinopathy, there is evidence that fenofibrate may be more effective at reducing the progression of retinal damage. [4]

Surgery

Instead of laser surgery, some people require a vitrectomy to restore vision. A vitrectomy is performed when there is a lot of blood in the vitreous. It involves removing the cloudy vitreous and replacing it with a saline solution.

Studies show that people who have a vitrectomy soon after a large hemorrhage are more likely to protect their vision than someone who waits to have the operation. Early vitrectomy is especially effective in people with insulin-dependent diabetes, who may be at greater risk of blindness from a hemorrhage into the eye.

Vitrectomy may be done under general or local anesthesia. The doctor makes a tiny incision in the sclera, or white of the eye. Next, a small instrument is placed into the eye to remove the vitreous and insert the saline solution into the eye.

Patients may be able to return home soon after the vitrectomy, or may be asked to stay in the hospital overnight. After the operation, the eye will be red and sensitive, and patients usually need to wear an eyepatch for a few days or weeks to protect the eye. Medicated eye drops are also prescribed to protect against infection. There is evidence which suggests anti-VEGF drugs given either prior to or during vitrectomy may reduce the risk of posterior vitreous cavity haemorrhage . [57] Vitrectomy is frequently combined with other modalities of treatment.

Epidemiology

Around 35% of people with diabetes have some kind of diabetic retinopathy; around 10% experience some degree of vision loss. [58] Diabetic retinopathy is particularly common in those with type 1 diabetes – affecting 25% of people five years from diagnosis, 60% 10 years from diagnosis, and 80% 15 years from diagnosis. [59] Chances of disease progression are heavily influenced by blood sugar control, but on average 7% of those with diabetes experiencing proliferative diabetic retinopathy and 7% diabetic macular edema. [58] Diabetic retinopathy is the leading cause of vision loss in those 20–74 years old. [58]

The global burden of diabetic retinopathy increased dramatically from 1990 to 2015—from 1.4 million to 2.6 million people with visual impairment; from 0.2 million to 0.4 million blinded—due in large part to the increasing burden of type 2 diabetes in low- and middle-income countries. [58]

Research

Several large multicenter randomized clinical trials have been done to evaluate treatment protocols for those with diabetic retinopathy, namely the Early Treatment for Diabetic Retinopathy Study, Diabetic Retinopathy Vitrectomy Study, Diabetic Retinopathy Study, Diabetes Control and Complications Trial, UK Prospective Diabetes Study, and the Diabetic Retinopathy Clinical Research Network Protocols I, S, and T. [60]

Light treatment

A medical device comprising a mask that delivers green light through the eyelids while a person sleeps was under development in 2016. [61] [62] The light from the mask stops rod cells in the retina from dark adapting, which is thought to reduce their oxygen requirement, which in turn diminishes new blood vessel formation and thus prevents diabetic retinopathy. [61] As of 2016 a large clinical trial was underway. [61] As of 2018, the results from the clinical trial showed no long-term therapeutic benefit from using the mask in diabetic retinopathy patients. [63]

C-peptide

C-peptide had shown promising results in treatment of diabetic complications incidental to vascular degeneration. [64] Creative Peptides, [65] Eli Lilly, [66] and Cebix [67] all had drug development programs for a C-peptide product. Cebix had the only ongoing program until it completed a Phase IIb trial in December 2014 that showed no difference between C-peptide and placebo, and it terminated its program and went out of business. [68] [69]

Stem cell therapy

Clinical trials are under way or are being populated in preparation for study at medical centers in Brazil, Iran and the United States. Current trials involve using the patients' own stem cells derived from bone marrow and injected into the degenerated areas in an effort to regenerate the vascular system. [70]

Blood pressure control

A Cochrane review examined 29 randomized controlled trials to determine whether interventions that sought to control or reduce blood pressure in diabetics had any effects of diabetic retinopathy. [71] While the results showed that interventions to control or reduce blood pressure prevented diabetic retinopathy for up to 4–5 years in diabetics, there was no evidence of any effect of these interventions on progression of diabetic retinopathy, preservation of visual acuity, adverse events, quality of life, and costs. [71]

Fundoscopic image analyses

Distribution in percentage of pre-processing techniques from 2011 to 2014 Image processing figure.jpg
Distribution in percentage of pre-processing techniques from 2011 to 2014

Diabetic retinopathy is diagnosed entirely by recognizing abnormalities on retinal images taken by fundoscopy. Color fundus photography is mainly used for staging the disease. Fluorescein angiography is used to assess the extent of retinopathy that aids in treatment plan development. Optical coherence tomography (OCT) is used to determine the severity of edema and treatment response. [73]

Because fundoscopic images are the main sources for diagnosis of diabetic retinopathy, manually analyzing those images can be time-consuming and unreliable, as the ability of detecting abnormalities varies by years of experience. [74] Therefore, scientists have explored developing computer-aided diagnosis approaches to automate the process, which involves extracting information about the blood vessels and any abnormal patterns from the rest of the fundoscopic image and analyzing them. [72]

See also

Related Research Articles

<span class="mw-page-title-main">Retinopathy</span> Damage to the retina of the eyes

Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Age-related macular degeneration is technically included under the umbrella term retinopathy but is often discussed as a separate entity. Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of systemic disease as seen in diabetes or hypertension. Diabetes is the most common cause of retinopathy in the U.S. as of 2008. Diabetic retinopathy is the leading cause of blindness in working-aged people. It accounts for about 5% of blindness worldwide and is designated a priority eye disease by the World Health Organization.

<span class="mw-page-title-main">Vitrectomy</span> Surgery to remove vitreous humor from the eye

Vitrectomy is a surgery to remove some or all of the vitreous humor from the eye.

<span class="mw-page-title-main">Retinoschisis</span> Eye disease involving splitting of the retina

Retinoschisis is an eye disease characterized by the abnormal splitting of the retina's neurosensory layers, usually in the outer plexiform layer. Retinoschisis can be divided into degenerative forms which are very common and almost exclusively involve the peripheral retina and hereditary forms which are rare and involve the central retina and sometimes the peripheral retina. The degenerative forms are asymptomatic and involve the peripheral retina only and do not affect the visual acuity. Some rarer forms result in a loss of vision in the corresponding visual field.

The National Eye Institute (NEI) is part of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NEI is "to eliminate vision loss and improve quality of life through vision research." NEI consists of two major branches for research: an extramural branch that funds studies outside NIH and an intramural branch that funds research on the NIH campus in Bethesda, Maryland. Most of the NEI budget funds extramural research.

Retinopathy of prematurity (ROP), also called retrolental fibroplasia (RLF) and Terry syndrome, is a disease of the eye affecting prematurely born babies generally having received neonatal intensive care, in which oxygen therapy is used because of the premature development of their lungs. It is thought to be caused by disorganized growth of retinal blood vessels and may result in scarring and retinal detachment. ROP can be mild and may resolve spontaneously, but it may lead to blindness in serious cases. Thus, all preterm babies are at risk for ROP, and very low birth-weight is an additional risk factor. Both oxygen toxicity and relative hypoxia can contribute to the development of ROP.

<span class="mw-page-title-main">Macular edema</span> Medical condition

Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye and causes it to thicken and swell (edema). The swelling may distort a person's central vision, because the macula holds tightly packed cones that provide sharp, clear, central vision to enable a person to see detail, form, and color that is directly in the centre of the field of view.

<span class="mw-page-title-main">Retinal detachment</span> Medical condition of the eye

Retinal detachment is a disorder of the eye in which the retina peels away from its underlying layer of support tissue. Initial detachment may be localized, but without rapid treatment the entire retina may detach, leading to vision loss and blindness. It is a surgical emergency.

Retinal hemorrhage is a disorder of the eye in which bleeding occurs in the retina, the light sensitive tissue, located on the back wall of the eye. There are photoreceptor cells in the retina called rods and cones, which transduce light energy into nerve signals that can be processed by the brain to form visual images. Retinal hemorrhage is strongly associated with child abuse in infants and young children and often leaves such abused infants permanently blind. In older children and adults, retinal hemorrhage can be caused by several medical conditions such as hypertension, retinal vein occlusion, anemia, leukemia or diabetes.

Eales disease is a type of obliterative vasculopathy, also known as angiopathia retinae juvenilis, periphlebitis retinae or primary perivasculitis of the retina. It was first described by the British ophthalmologist Henry Eales (1852–1913) in 1880 and is a rare ocular disease characterized by inflammation and possible blockage of retinal blood vessels, abnormal growth of new blood vessels (neovascularization), and recurrent retinal and vitreal hemorrhages.

<span class="mw-page-title-main">Epiretinal membrane</span> Eye disease

Epiretinal membrane or macular pucker is a disease of the eye in response to changes in the vitreous humor or more rarely, diabetes. Sometimes, as a result of immune system response to protect the retina, cells converge in the macular area as the vitreous ages and pulls away in posterior vitreous detachment (PVD).

<span class="mw-page-title-main">Intraocular hemorrhage</span> Medical condition

Intraocular hemorrhage is bleeding inside the eye. Bleeding can occur from any structure of the eye where there is vasculature or blood flow, including the anterior chamber, vitreous cavity, retina, choroid, suprachoroidal space, or optic disc.

<span class="mw-page-title-main">Macular telangiectasia</span> Disease of the retina affecting central vision

Macular telangiectasia is a condition of the retina, the light-sensing tissue at the back of the eye that causes gradual deterioration of central vision, interfering with tasks such as reading and driving.

<span class="mw-page-title-main">Laser coagulation</span> Procedure widely used in eye surgery

Laser coagulation or laser photocoagulation surgery is used to treat a number of eye diseases and has become widely used in recent decades. During the procedure, a laser is used to finely cauterize ocular blood vessels to attempt to bring about various therapeutic benefits.

<span class="mw-page-title-main">Vitreous hemorrhage</span> Leakage of blood into the internal fluid of the eye

Vitreous hemorrhage is the extravasation, or leakage, of blood into the areas in and around the vitreous humor of the eye. The vitreous humor is the clear gel that fills the space between the lens and the retina of the eye. A variety of conditions can result in blood leaking into the vitreous humor, which can cause impaired vision, floaters, and photopsia.

<span class="mw-page-title-main">Branch retinal vein occlusion</span> Medical condition

Branch retinal vein occlusion is a common retinal vascular disease of the elderly. It is caused by the occlusion of one of the branches of central retinal vein.

<span class="mw-page-title-main">Vitreomacular adhesion</span> Human medical condition

Vitreomacular adhesion (VMA) is a human medical condition where the vitreous gel of the human eye adheres to the retina in an abnormally strong manner. As the eye ages, it is common for the vitreous to separate from the retina. But if this separation is not complete, i.e. there is still an adhesion, this can create pulling forces on the retina that may result in subsequent loss or distortion of vision. The adhesion in of itself is not dangerous, but the resulting pathological vitreomacular traction (VMT) can cause severe ocular damage.

<span class="mw-page-title-main">Radiation retinopathy</span> Medical condition

Radiation retinopathy is damage to retina due to exposure to ionizing radiation. Radiation retinopathy has a delayed onset, typically after months or years of radiation, and is slowly progressive. In general, radiation retinopathy is seen around 18 months after treatment with external-beam radiation and with brachytherapy. The time of onset of radiation retinopathy is between 6 months to 3 years.

<span class="mw-page-title-main">Intravitreal injection</span> Method of administration of drugs into the eye by injection with a fine needle

Intravitreal injection is the method of administration of drugs into the eye by injection with a fine needle. The medication will be directly applied into the vitreous humor. It is used to treat various eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and infections inside the eye such as endophthalmitis. As compared to topical administration, this method is beneficial for a more localized delivery of medications to the targeted site, as the needle can directly pass through the anatomical eye barrier and dynamic barrier. It could also minimize adverse drug effects on other body tissues via the systemic circulation, which could be a possible risk for intravenous injection of medications. Although there are risks of infections or other complications, with suitable precautions throughout the injection process, chances for these complications could be lowered.

Sickle cell retinopathy can be defined as retinal changes due to blood vessel damage in the eye of a person with a background of sickle cell disease. It can likely progress to loss of vision in late stages due to vitreous hemorrhage or retinal detachment. Sickle cell disease is a structural red blood cell disorder leading to consequences in multiple systems. It is characterized by chronic red blood cell destruction, vascular injury, and tissue ischemia causing damage to the brain, eyes, heart, lungs, kidneys, spleen, and musculoskeletal system.

Drug abuse retinopathy is damage to the retina of the eyes caused by chronic drug abuse. Types of retinopathy caused by drug abuse include maculopathy, Saturday night retinopathy, and talc retinopathy. Common symptoms include temporary and permanent vision loss, blurred vision, and night blindness. Substances commonly associated with this condition include poppers, heroin, cocaine, methamphetamine, tobacco, and alcohol.

References

  1. ↑ "Retinopathy | Definition of Retinopathy by Oxford Dictionary". lexico.com. Archived from the original on January 14, 2021.
  2. 1 2 3 "Diabetic retinopathy - Diagnosis and treatment". mayoclinic.org. Mayo Clinic.
  3. ↑ Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. (January 2004). "Retinopathy in diabetes". Diabetes Care. 27 (Suppl 1). American Diabetes Association: S84–S87. doi: 10.2337/diacare.27.2007.S84 . PMID   14693935.
  4. 1 2 3 4 Kataoka SY, Lois N, Kawano S, Kataoka Y, Inoue K, Watanabe N (June 2023). "Fenofibrate for diabetic retinopathy". The Cochrane Database of Systematic Reviews. 6 (6): CD013318. doi:10.1002/14651858.CD013318.pub2. PMC   10264082 . PMID   37310870.
  5. 1 2 3 4 5 6 7 Brownlee et al. 2020, "Clinical features of diabetic retinopathy".
  6. 1 2 "Vision Loss". Centers for Disease Control and Prevention. 7 May 2021. Retrieved 20 October 2022.
  7. 1 2 "Macular Edema". National Eye Institute. 5 August 2022. Retrieved 28 October 2022.
  8. ↑ Aiello et al. 2016, "Diabetic macular edema, ischemia, and traction".
  9. ↑ Brownlee et al. 2020, "Pathophysiology of diabetic retinopathy".
  10. ↑ "Retinal Detachment". Diabetes.co.uk. 10 June 2022. Retrieved 28 October 2022.
  11. 1 2 3 Lim 2019, "Diagnosis and ancillary testing".
  12. ↑ Aiello et al. 2016, "Detection".
  13. ↑ Lim 2019, "Epidemiology".
  14. 1 2 3 Vujosevic et al. 2020, "Screening for diabetic retinopathy: who, when, and how".
  15. ↑ Vujosevic et al. 2020, "Development of nationwide screening programs".
  16. ↑ "Diabetic eye screening – NHS Choices". NHS Choices. 12 July 2016.
  17. ↑ "Diabetic eye screening". 2017-10-18.
  18. ↑ Gupta A, Cavallerano J, Sun JK, Silva PS (17 October 2016). "Evidence for Telemedicine for Diabetic Retinal Disease". Seminars in Ophthalmology. 32 (1): 22–28. doi:10.1080/08820538.2016.1228403. PMID   27748634. S2CID   1335693.
  19. ↑ World Health Organization 2020, pp. 9.
  20. ↑ Powers, Stafford & Rickels 2022, "Mechanisms of Complications".
  21. 1 2 3 Powers, Stafford & Rickels 2022, "Ophthalmologic Complications of Diabetes".
  22. ↑ Vujosevic et al. 2020, "Risk factors for diabetic retinopathy".
  23. 1 2 3 Brownlee et al. 2020, "Initial ophthalmic evaluation".
  24. 1 2 Lin et al. 2021, "Risk factors, preventive factors, and biomarkers".
  25. 1 2 Forrest IS, Chaudhary K, Paranjpe I, Vy HM, Marquez-Luna C, Rocheleau G, et al. (May 2021). "Genome-wide polygenic risk score for retinopathy of type 2 diabetes". Human Molecular Genetics. 30 (10): 952–960. doi:10.1093/hmg/ddab067. PMC   8165647 . PMID   33704450.
  26. ↑ Tan et al. 2017, "Risk factors".
  27. ↑ Ryeom S, Folkman J (March 2009). "Role of endogenous angiogenesis inhibitors in Down syndrome". The Journal of Craniofacial Surgery. 20 (Suppl 1): 595–596. doi:10.1097/SCS.0b013e3181927f47. PMID   19795527. S2CID   21576950.
  28. ↑ de Gooyer TE, Stevenson KA, Humphries P, Simpson DA, Gardiner TA, Stitt AW (December 2006). "Retinopathy is reduced during experimental diabetes in a mouse model of outer retinal degeneration". Investigative Ophthalmology & Visual Science. 47 (12): 5561–5568. doi: 10.1167/iovs.06-0647 . PMID   17122149.
  29. ↑ "Diabetes and Vision". News-Medical.net. 2018-04-04. Retrieved 2018-04-10.
  30. 1 2 Xu H, Curtis T, Stitt A (13 August 2013). "Pathophysiology and Pathogenesis of Diabetic Retinopathy [internet]". Diapedia. 7104343513 (14). doi:10.14496/dia.7104343513.14 (inactive 2024-09-18). Retrieved 26 August 2016.{{cite journal}}: CS1 maint: DOI inactive as of September 2024 (link)
  31. ↑ Pardianto G (2005). "Understanding diabetic retinopathy". Mimbar Ilmiah Oftalmologi Indonesia. 2: 65–6.
  32. ↑ Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, et al. (November 2009). "Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy". Nature Medicine. 15 (11): 1298–1306. doi:10.1038/nm.2052. PMC   3290906 . PMID   19881493.
  33. ↑ Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R (2013). "Pathophysiology of diabetic retinopathy". ISRN Ophthalmology. 2013: 343560. doi: 10.1155/2013/343560 . PMC   3914226 . PMID   24563789.
  34. ↑ Shivashankar G, Lim JC, Acosta ML (2023-02-28). "Proinflammatory Cytokines Trigger the Onset of Retinal Abnormalities and Metabolic Dysregulation in a Hyperglycemic Mouse Model". Journal of Ophthalmology. 2023: 7893104. doi: 10.1155/2023/7893104 . PMC   9991478 . PMID   36895267.
  35. ↑ Shivashankar G, Lim JC, Acosta ML (2020). "Proinflammatory cytokines trigger biochemical and neurochemical changes in mouse retinal explants exposed to hyperglycemic conditions". Molecular Vision. 26: 277–290. PMC   7155896 . PMID   32300272.
  36. ↑ Njie-Mbye YF, Kulkarni-Chitnis M, Opere CA, Barrett A, Ohia SE (December 2013). "Lipid peroxidation: pathophysiological and pharmacological implications in the eye". Frontiers in Physiology. 4: 366. doi: 10.3389/fphys.2013.00366 . PMC   3863722 . PMID   24379787.
  37. ↑ Martinez-Zapata MJ, Salvador I, Martí-Carvajal AJ, Pijoan JI, Cordero JA, Ponomarev D, et al. (March 2023). "Anti-vascular endothelial growth factor for proliferative diabetic retinopathy". The Cochrane Database of Systematic Reviews. 3 (3): CD008721. doi:10.1002/14651858.CD008721.pub3. PMC   10026605 . PMID   36939655.
  38. ↑ Flaxel et al. 2020, "Early detection of diabetic retinopathy".
  39. ↑ Mitchell P, Wong TY (March 2014). "Management paradigms for diabetic macular edema". American Journal of Ophthalmology. 157 (3): 505–13.e1–8. doi:10.1016/j.ajo.2013.11.012. PMID   24269850.
  40. 1 2 3 Lin et al. 2021, "Treatments".
  41. ↑ Flaxel et al. 2020, "Mild to moderate NPDR without macular edema".
  42. ↑ Brownlee et al. 2020, "Treatment of nonproliferative diabetic retinopathy”.
  43. ↑ Ngah NF, Muhamad NA, Abdul Aziz RA, Mohamed SO, Ahmad Tarmizi NA, Adnan A, et al. (2022-12-18). "Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy: review, consensus recommendations and guidance for clinical practice". International Journal of Ophthalmology. 15 (12): 2001–2008. doi:10.18240/ijo.2022.12.16. PMC   9729076 . PMID   36536974.
  44. ↑ "Trial: Fenofibrate Slows Diabetic Retinopathy Progression". Medscape. Retrieved 2024-07-29.
  45. ↑ Flaxel et al. 2020, "Anti-Vascular Endothelial Growth Factor Therapy".
  46. ↑ Kuroiwa, Malerbi & Regatieri 2021, "Laser".
  47. ↑ Flaxel et al. 2020, "Treatment Deferral".
  48. ↑ Šimčíková D, Ivančinová J, Veith M, Dusová J, Matušková V, Němčanský J, et al. (June 2024). "Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset". Diabetes Research and Clinical Practice. 212 (1): 111721. doi:10.1016/j.diabres.2024.111721. PMID   38821414.
  49. ↑ Jorge EC, Jorge EN, Botelho M, Farat JG, Virgili G, El Dib R, et al. (Cochrane Eyes and Vision Group) (October 2018). "Monotherapy laser photocoagulation for diabetic macular oedema". The Cochrane Database of Systematic Reviews. 2018 (10): CD010859. doi:10.1002/14651858.CD010859.pub2. PMC   6516994 . PMID   30320466.
  50. ↑ Moutray T, Evans JR, Lois N, Armstrong DJ, Peto T, Azuara-Blanco A (March 2018). "Different lasers and techniques for proliferative diabetic retinopathy". The Cochrane Database of Systematic Reviews. 2018 (3): CD012314. doi:10.1002/14651858.cd012314.pub2. PMC   6494342 . PMID   29543992.
  51. ↑ Kertes PJ, Johnson TM, eds. (2007). Evidence Based Eye Care. Philadelphia, PA: Lippincott Williams & Wilkins. ISBN   978-0-7817-6964-8.[ page needed ]
  52. ↑ Amoroso F, Pedinielli A, Astroz P, Semoun O, Capuano V, Miere A, et al. (May 2020). "Comparison of pain experience and time required for pre-planned navigated peripheral laser versus conventional multispot laser in the treatment of diabetic retinopathy". Acta Diabetologica. 57 (5): 535–541. doi:10.1007/s00592-019-01455-x. PMID   31749047. S2CID   208172191.
  53. ↑ Chhablani J, Mathai A, Rani P, Gupta V, Arevalo JF, Kozak I (May 2014). "Comparison of conventional pattern and novel navigated panretinal photocoagulation in proliferative diabetic retinopathy". Investigative Ophthalmology & Visual Science. 55 (6): 3432–3438. doi:10.1167/iovs.14-13936. PMID   24787564.
  54. 1 2 Rittiphairoj T, Mir TA, Li T, Virgili G (November 2020). "Intravitreal steroids for macular edema in diabetes". The Cochrane Database of Systematic Reviews. 2020 (11): CD005656. doi:10.1002/14651858.CD005656.pub3. PMC   8095060 . PMID   33206392.
  55. ↑ Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M, et al. (Cochrane Eyes and Vision Group) (June 2023). "Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2023 (6): CD007419. doi:10.1002/14651858.CD007419.pub7. PMC   10294542 . PMID   38275741.
  56. ↑ Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, et al. (December 2020). "Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial". Jama. 324 (23): 2383–2395. doi:10.1001/jama.2020.23027. PMC   7739132 . PMID   33320223.
  57. ↑ Dervenis P, Dervenis N, Smith JM, Steel DH (May 2023). "Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy". The Cochrane Database of Systematic Reviews. 2023 (5): CD008214. doi:10.1002/14651858.CD008214.pub4. PMC   10230853 . PMID   37260074.
  58. 1 2 3 4 Vujosevic et al. 2020, "Introduction".
  59. ↑ Brownlee et al. 2020, "Epidemiology and Impact of Proliferative Diabetic Retinopathy and Diabetic Macular Edema".
  60. ↑ Brownlee et al. 2020, "Monitoring and treatment of diabetic retinopathy".
  61. 1 2 3 Sivaprasad S, Arden G (February 2016). "Spare the rods and spoil the retina: revisited". Eye. 30 (2): 189–192. doi:10.1038/eye.2015.254. PMC   4763134 . PMID   26656085.
  62. ↑ "Noctura 400 Sleep Mask for diabetic retinopathy". NIHR Innovation Observatory. Retrieved 2022-02-15.
  63. ↑ Powell S. "No "long-term therapeutic benefit" from £250 mask". www.aop.org.uk. Retrieved 2022-02-15.
  64. ↑ Bhatt MP, Lim YC, Ha KS (November 2014). "C-peptide replacement therapy as an emerging strategy for preventing diabetic vasculopathy". Cardiovascular Research. 104 (2): 234–244. doi: 10.1093/cvr/cvu211 . PMID   25239825.
  65. ↑ "C-peptide - Creative Peptides -". AdisInsight. Retrieved 22 October 2016.
  66. ↑ "C-peptide – Eli Lilly". AdisInsight. Retrieved 22 October 2016.
  67. ↑ "C-peptide long-acting – Cebix". adisinsight.springer.com. AdisInsight. Retrieved 22 October 2016.
  68. ↑ Bigelow BV (23 February 2015). "Cebix Shuts Down Following Mid-Stage Trial of C-Peptide Drug". Xconomy.
  69. ↑ Garde D (February 24, 2015). "Cebix hangs it up after raising $50M for diabetes drug". FierceBiotech.
  70. ↑ Ljubimov A. "Stem Cell Therapy for Diabetic Retinopathy" (PDF). Cedars-Sinai Medical Center, Regenerative Medicine Institute, Los Angeles, CA, USA Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Archived from the original (PDF) on 2014-12-30. Retrieved 2014-12-30.
  71. 1 2 Do DV, Han G, Abariga SA, Sleilati G, Vedula SS, Hawkins BS (March 2023). "Blood pressure control for diabetic retinopathy". The Cochrane Database of Systematic Reviews. 2023 (3): CD006127. doi:10.1002/14651858.CD006127.pub3. PMC   10049880 . PMID   36975019.
  72. 1 2 Ahmad A, Mansoor AB, Mumtaz R, Khan M, Mirza SH (2014-12-01). "Image processing and classification in diabetic retinopathy: A review". 2014 5th European Workshop on Visual Information Processing (EUVIP). pp. 1–6. doi:10.1109/EUVIP.2014.7018362. ISBN   978-1-4799-4572-6. S2CID   16465894.
  73. ↑ "Diabetic Retinopathy". Merck Manuals Professional Edition. Retrieved 2016-11-13.
  74. ↑ Kaur M, Talwar R (2014). "Review on: Blood Vessel Extraction and Eye Retinopathy Detection". International Journal of Computer Science and Information Technologies. 5 (6): 7513–7516.
  75. ↑ Grossman S. "A New Treatment for Diabetic Retinopathy". Diabetescare.net. Retrieved 19 March 2015.

Works cited

PD-icon.svg  This article incorporates text from a publication in the public domain:  "Facts About Diabetic Retinopathy". National Eye Institute, National Institutes of Health (NEI/NIH). June 2012. Archived from the original on 12 May 2014. Retrieved 13 June 2002.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.